Germany Pegfilgrastim- Biosimilar Market Analysis

Germany Pegfilgrastim- Biosimilar Market Analysis


$ 3999

Germany Pegfilgrastim- Biosimilar market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for Pegfilgrastim- Biosimilar is growing rapidly as a result of rising demand for biosimilars because they are cost effective, increasing demand for oncology supportive care due to rising cases of oncology and chronic diseases globally including HIV/AIDS, expiration of patents of key innovator drugs, support from regulatory body’s like pathways for the approval of biosimilars, strong investments in healthcare infrastructure and in research and development. Merck & Co., Inc., Zydus Lifesciences Limited, Ratiopharm GmbH, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Biocon Limited, Dr. Reddy's Laboratories Ltd, Pfizer Inc., Emcure Pharmaceuticals Limited, USV Private Limited, and Apotex Pty Ltd. are important market participants for pegfilgrastim biosimilars.

ID: IN10DEPH360 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Riddhi Solanki

Buy Now

Germany Pegfilgrastim- Biosimilar Market Analysis Summary

Germany Pegfilgrastim- Biosimilar Market is valued at around $49.2 Mn in 2022 and is projected to reach $93.7 Mn by 2030, exhibiting a CAGR of 8.4% during the forecast period 2023-2030.

Pegfilgrastim is a drug used in the treatment of cancer and blood disorders. It is a long-acting version of the recombinant human granulocyte colony-stimulating factor (G-CSF) medication filgrastim. Pegfilgrastim is primarily used to prevent or lessen the severity of neutropenia, a condition marked by low levels of neutrophils (a kind of white blood cell). Pegfilgrastim promotes the formation of white blood cells in the bone marrow. Chemotherapy, particularly specific cancer therapies that inhibit bone marrow activity, can have the side effect of neutropenia. Pegfilgrastim helps chemotherapy patients have fewer infections by increasing the production of neutrophils. Pegfilgrastim is frequently given as a subcutaneous injection, and because it has a longer half-life than filgrastim, it can be dosed less frequently. It is offered under numerous brand names, such as Fulphila, Ziextenzo, and Neulasta. Merck & Co., Inc., Zydus Lifesciences Limited, Ratiopharm GmbH, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Biocon Limited, Dr. Reddy's Laboratories Ltd, Pfizer Inc., Emcure Pharmaceuticals Limited, USV Private Limited, and Apotex Pty Ltd. are important market participants for pegfilgrastim biosimilars.

Market Dynamics

Market Growth Drivers

The cost-effective nature of biosimilars as compared to original biologicals, increasing demand for oncology supportive care due to rising cases of oncology and chronic diseases globally including HIV/AIDS, expiration of patents of key innovator drugs, support from regulatory bodies like developments of pathways for the approval of biosimilars, strong investments in healthcare infrastructure and research and development. the growing number of company collaborations, increased production, and awareness, etc. All these factors act as market growth drivers in the global pegfilgrastim-biosimilar market.

Market Restraints

Several adverse effects are associated with pegfilgrastim biosimilars like acute respiratory distress syndrome, bone pain, and spleen rupture.

Issues with intellectual property and patents: The reference drug for pegfilgrastim may still be covered by patents that are still in effect or that are protected by intellectual property laws in some places, preventing the introduction of rival biosimilar products until those patents expire.

Physician and Patient Acceptance issues due to rising concerns about safety and efficacy and manufacturing Complexities to ensure product quality, purity, and consistency.

Reimbursement and Market Access coverage issues. All these act as market growth restraints.?

Competitive Landscape

Key Player

  • Merck & Co., Inc.
  • Zydus Lifesciences Limited
  • Ratiopharm GmbH
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd
  • Pfizer Inc.
  • Emcure Pharmaceuticals Limited
  • USV Private Limited
  • Apotex Pty Ltd.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Germany Pegfilgrastim - Biosimilar Market Segmentations

By Indication Type

  • Neutropenia
  • Hematopoietic Subsyndrome
  • Others

By Product Type

  • MK-6302
  • Peg G-CSF
  • PEG Neutrogena
  • Grasustek
  • LA-EP2006
  • R-TPR-029
  • Filgrastim
  • PEG-GCSF
  • Others

 By Application

  • Chemotherapy Induced Neutropenia
  • Transplantation
  • Others

By Distribution Channel

  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up